Orchestra BioMed Holdings (OBIO) Total Current Liabilities (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Total Current Liabilities for 7 consecutive years, with $13.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 11.6% year-over-year to $13.7 million; the TTM figure through Mar 2026 stood at $13.7 million (down 11.6% YoY), while the FY2025 annual figure was $16.7 million, up 3.26% from the prior year.
• Total Current Liabilities eased to $13.7 million in Q1 2026 per OBIO's latest filing, from $16.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $21.5 million in Q3 2023 and bottomed at $306538.0 in Q1 2022.
• Historically, Total Current Liabilities has averaged $12.9 million across 5 years, with a median of $14.5 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 11115.48% — and 2023, when it plunged 39.63%.
• Orchestra BioMed Holdings' Total Current Liabilities stood at $18.6 million in 2022, then slumped by 39.63% to $11.2 million in 2023, then jumped by 44.6% to $16.2 million in 2024, then gained by 3.26% to $16.7 million in 2025, then dropped by 18.19% to $13.7 million in 2026.
• Business Quant data shows OBIO's Total Current Liabilities at $13.7 million in Q1 2026, $16.7 million in Q4 2025, and $20.7 million in Q3 2025.